Within the scope of cancer immunotherapy, the role of human T cell receptors (TCRs) in recognizing NRAS cancer neoantigens with AlphaFold3’s predictions was validated using experimental techniques such as peptide–MHC tetramer staining and TCR engagement assays to confirm the structural accuracy and binding specificity [38]. The gene discussed is HLA-C; the disease is cancer.